Gemcitabine alone is the standard chemotherapeutic agent
for patients with locally advanced or metastatic pancreatic cancer.
With this therapy, the incidence of drug toxicities is diminished, and
patients report greater improvement in quality of life than that which occurred
with previous regimens. Additionally, early trials have demonstrated a modest
but significant survival advantage for patients treated with gemcitabine.
